| 영문 | insulin | 한글 | 인슐린 |
|---|---|---|---|
| 설명 | 이자 랑겔한스섬의 B세포가 합성-분비하는 호르몬 단백질, 포도당을 글리코겐으로 바꾸는 호르몬단백질로, 분자량은 5,807이다. 혈중의 당농도 상승으로 인하여 분비가 촉진된다. 근육-지방조직-간 등 표적세포의 수용체 단백질과 결합하여 정보를 세포내로 전달함으로써 혈액 중에서 당, 지질, 아미노산 대사를 조절한다. 당의 조직에 받아드리는 것을 촉진하여 혈당을 저하시킨다. 생성-분비량 저하, 조직세포의 수용체 부족은 고혈당의 원인이 된다. 또한 아미노산의 흡수와 단백질, 지방의 합성을 촉진하며 지방분해는 억제한다. 인슐린은 이자활성성분의 약품으로서 당뇨병 및 기타 질환의 치료에 사용된다. 인슐린이라는 명칭은 섬이란 뜻의 라틴어인 insula에서 연유한다. 1921년 캐나다의 의사 F.G. 밴팅과 C.H. 베스트에 의하여 처음으로 이자에서 채취되었고, 그 후 인슐린의 결정을 얻게 되었다. F. 생거에 의해서 소의 인슐린의 구조가 밝혀졌는데(1955), 이것은 단백질 중에서는 최초로 구조식이 밝혀진 것이다. 포도당으로부터 글리코겐의 생성, 포도당의 산화 및 지방으로의 전화 등을 촉진하는 작용이 있다. 따라서 인슐린의 수용액을 주사하면 혈당이 저하하므로 당뇨병의 치료에 쓰인다. 또 인슐린을 피하에 대량 주사하면 혼수에 빠지는 것을 이용하여 정신병 치료에 인슐린쇼크요법으로서 쓰인다. |
||
| 영문 | IDDM(Insulin-Dependent Diabetes Mellitus) | 한글 | 인슐린의존당뇨병 |
|---|---|---|---|
| 설명 | IDDM은 당뇨병의 치료에 반드시 인슐린이 필요한 경우를 말한다. 주로 원인이 이자에 있는 인슐린을 분비하는 세포의 파괴이며 이로 인해서 당뇨병의 치료제로 쓰이는 인슐린의 분비를 촉진하는 약물이 이 IDDM에서는 쓰일 수가 없고 오직 인슐린만이 치료제로 쓸 수가 있다. 전형적인 인슐린 의존형 당뇨병은 소아에서 흔히 발생하고 인슐린 분비세포의 파괴에 의해서 인슐린 분비능은 거의 없다. |
||
| antag | antagonist |
|---|---|
| CA | anterior commissure [Lat. commissura anterior]; calcium antagonist; California [rabbit]; cancer; Can... |
| FAA | folic acid antagonist; formaldehyde, acetic acid, alcohol |
| NPH | 1) Neutral Protamine Hagedorn Insulin = Isophane Insulin Susp... |
| AITT | arginine insulin tolerance test; augmented insulin tolerance test |
| Ant | Antagonist |
|---|---|
| CA | calcium antagonist |
| GnRH-A | GnRH antagonist |
| H2-RA | Histamine-2 receptor antagonist |
| IL 1ra | IL 1 receptor antagonist |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| insulin antagonist | Something that opposes or fights the action of insulin. Insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it, therefore, glucagon is an antagonist of insulin. (09 Oct 1997) |
|---|
| aldosterone antagonist | An agent that opposes the action of the adrenal hormone aldosterone on renal tubular mineralocorticoid retention; these agents, e.g., spironolactone, are useful in treating the hypertension of primary hyperaldosteronism, or the sodium retention of secondary hyperaldosteronism. (05 Mar 2000) |
|---|---|
| antagonist | <pharmacology> A substance that tends to nullify the action of another, as a drug that binds to a cell receptor without eliciting a biological response. Origin: Gr. Antagonistes = an opponent (18 Nov 1997) |
| associated antagonist | One of two muscles or groups of muscles which pull in nearly opposite directions, but which, when acting together, move the part in a path between their diverging lines of action. (05 Mar 2000) |
| beta-adrenoreceptor antagonist | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| calcium antagonist | calcium channel-blocking agent |
| calcium channel antagonist | <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools. Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms. Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent. (12 May 2002) |
| mixed opioid agonist-antagonist | <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type. (13 Nov 1997) |
| competitive antagonist | An antimetabolite. (05 Mar 2000) |
| muscarinic antagonist | Drugs which bind with muscarinic cholinergic receptors but do not activate them, thus preventing access to acetylcholine; examples include atropine, scopolamine, propantheline, and pirenzepine. (05 Mar 2000) |
| H2 antagonist | <pharmacology> A class of anti-ulcer medication which work through the inhibition of basal and nocturnal gastric acid secretion by competitive inhibition of the action of histamine at histamine H2 receptor sites on the parietal cells. Drugs of this type block gastric acid secretion and are therefore clinically useful in treating duodenal ulcers. Examples include cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid) and ranitidine (Zantac). (27 Sep 1997) |
| oestrogen antagonist | <pharmacology> A drug or compound which inhibit or antagonise the action or biosynthesis of oestrogen. Tamoxifen also has agonist or stimulatory actions as well as blocking effects. There are also selective oestrogen-receptor modulators (SERMs). For example, raloxifene (trade name Evista) is classified as a SERM because it prevents bone loss (like oestrogen) and lowers serum cholesterol (like oestrogen) but (unlike oestrogen) does not stimulate the endometrial lining of the uterus. (12 May 2002) |
| enzyme antagonist | An antimetabolite or inhibitor of enzyme action. (05 Mar 2000) |
| folate antagonist | <pharmacology> One of a group of substances which blocks the formation of nucleotides that require the presence of folate (one of the B vitamins) before they can be made. The substance does this by blocking key steps in the reaction sequence. These substances are often used to treat cancer because fast-growing cancerous cells usually need to use the blocked reactions more than normal cells. (09 Oct 1997) |
| folic acid antagonist | <pharmacology> A chemical which inhibits a cells capacity to use folic acid and so prevent cell division, for example methotrexate. See: chemotherapy. (12 Nov 1997) |
| amorphous insulin zinc suspension | Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection. Synonym: amorphous insulin zinc suspension, semilente insulin. (05 Mar 2000) |
Synonyms : Antagonists, Insulin
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|